IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v24y2006i1p49-59.html
   My bibliography  Save this article

Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain

Author

Listed:
  • Arran Shearer
  • Adrian Bagust
  • F. Ampudia-Blasco
  • Belén Martínez-Lage Álvarez
  • Isabel Pérez Escolano
  • Gonzalo París

Abstract

Objective: To assess the lifetime diabetes health consequences and cost-effectiveness in Spain of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in overweight and obese patients failing to maintain glycaemic control with metformin monotherapy compared with conventional care of metformin in combination with either sulfonylureas or bedtime insulin. Research design and methods: The Diabetes Decision Analysis of Cost — Type 2 was adapted for clinical practice and healthcare funding in Spain, and was calibrated with Spanish epidemiological, healthcare resource use and cost data, taking the perspective of the Spanish National Health System. The model simulates lifetime treatment histories, complications and consequences of type 2 diabetes, and associated health outcomes and costs for age and sex-matched cohorts of 1000 overweight and obese patients. The primary health outcome measures compared are glycaemic control, time to insulin, incidence and prevalence of coronary heart disease, stroke, clinical nephropathy, ulceration and amputation, and severe visual loss, and incremental life-years and quality-adjusted life-years (QALYs). Results: Rosiglitazone in combination with metformin produces better glycaemic control than conventional care of metformin in combination with either sulfonylureas or bedtime insulin in most patients, and extends the viability of combination therapy by between 6 and 13 years before requiring insulin. Rosiglitazone patients have a longer life expectancy, gaining between 106 and 175 additional life-years per 1000 patients, experience fewer episodes of coronary disease and clinical nephropathy, and live for longer periods free of complications. The improvements in morbidity and mortality are projected to yield between 134 and 238 additional QALY per 1000 patients over their lifetime. Discounted incremental cost-effectiveness ratios range from €9406 to €23 514 per QALY gained. Conclusion: The model predicts that rosiglitazone in combination with metformin is a cost-effective intervention for the treatment of both overweight and obese patients with type 2 diabetes when compared with conventional care in Spain. Copyright Adis Data Information BV 2006

Suggested Citation

  • Arran Shearer & Adrian Bagust & F. Ampudia-Blasco & Belén Martínez-Lage Álvarez & Isabel Pérez Escolano & Gonzalo París, 2006. "Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain," PharmacoEconomics, Springer, vol. 24(1), pages 49-59, November.
    • Handle: RePEc:spr:pharme:v:24:y:2006:i:1:p:49-59
    DOI: 10.2165/00019053-200624001-00005
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200624001-00005
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200624001-00005?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Arran Shearer & Adrian Bagust & Andreas Liebl & Oliver Schoeffski & Anita Goertz, 2006. "Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany," PharmacoEconomics, Springer, vol. 24(1), pages 35-48, November.
    2. Oliva Moreno, Juan & Lobo, Félix & Molina, Begoña & Monereo, Susana, 2003. "Direct healthcare costs of diabetes mellitus patients in Spain," UC3M Working papers. Economics we036827, Universidad Carlos III de Madrid. Departamento de Economía.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Andrew Palmer & Craig Currie, 2006. "Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes," PharmacoEconomics, Springer, vol. 24(9), pages 927-929, September.
    2. Adrian Bagust & Marc Evans & Sophie Beale & Philip Home & Andrew Perry & Murray Stewart & Arran Shearer & Alan Martin & Lisa Hulme & Andreas Liebl & Oliver Schoeffski & Anita Goertz & Javier Ampudia-B, 2006. "The Authors’ Reply," PharmacoEconomics, Springer, vol. 24(9), pages 929-935, September.
    3. José Rodríguez Barrios & Ferran Pérez Alcántara & Carlos Crespo Palomo & Paloma González García & Enrique Antón De Las Heras & Max Brosa Riestra, 2012. "The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(6), pages 723-740, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Tatiana Dilla & Amparo Valladares & Claudia Nicolay & Javier Salvador & Jesús Reviriego & María Costi, 2012. "Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain," Applied Health Economics and Health Policy, Springer, vol. 10(6), pages 417-430, November.
    2. Till Seuring & Olga Archangelidi & Marc Suhrcke, 2015. "The Economic Costs of Type 2 Diabetes: A Global Systematic Review," PharmacoEconomics, Springer, vol. 33(8), pages 811-831, August.
    3. Juan Oliva-Moreno & Julio López-Bastida & Rubén Osuna-Guerrero & Angel Montejo-González & Beatriz Duque-González, 2006. "The costs of schizophrenia in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(3), pages 179-184, September.
    4. Andrew Palmer & Craig Currie, 2006. "Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes," PharmacoEconomics, Springer, vol. 24(9), pages 927-929, September.
    5. David Nathanson & Ugne Sabale & Jan W. Eriksson & Thomas Nyström & Anna Norhammar & Urban Olsson & Johan Bodegård, 2018. "Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014," PharmacoEconomics - Open, Springer, vol. 2(4), pages 393-402, December.
    6. Travis Minor, 2011. "The effect of diabetes on female labor force decisions: new evidence from the National Health Interview Survey," Health Economics, John Wiley & Sons, Ltd., vol. 20(12), pages 1468-1486, December.
    7. Mehdi Javanbakht & Hamid R Baradaran & Atefeh Mashayekhi & Ali Akbar Haghdoost & Mohammad E Khamseh & Erfan Kharazmi & Aboozar Sadeghi, 2011. "Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in Iran," PLOS ONE, Public Library of Science, vol. 6(10), pages 1-7, October.
    8. Ebere Akobundu & Jing Ju & Lisa Blatt & C. Mullins, 2006. "Cost-of-Illness Studies," PharmacoEconomics, Springer, vol. 24(9), pages 869-890, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:24:y:2006:i:1:p:49-59. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.